We are glad to announce that we received the U.S. FDA approval for use in treating benign pigmented lesions(including but not limited to solar lentignies, ephilides, mottled pigmentation) and benign vascular lesions(diffuse redness), as well as for hair removal(permanent hair reduction) dated on Jan.24, 2008.This is the first achievement for IPL manufacturers in Korea.